Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group Anne-Sophie Michallet , Anne Quinquenel , Remi Letestu , Tavernier Magali , Stephane Morisset , Therese Aurran , Kamel Laribi , Florence Cymbalista , Vincent Levy , Laurence Simon , Damien Roos Weil , Veronique Leblond , Marie Sarah Dilhuydy , Cecile Tomowiak , Caroline Dartigeas , Romain Guieze , Olivier Tournilhac , Emmanuelle Ferrant , Sophie De Guibert , Pierre Feugier , Fatiha Merabet , Stephane Lepretre , Philippe Carassou , Julie Gay , Benedicte Hivert , Luc Matthieu Fornecker , Jehan Dupuis , Lysiane Molina , Bruno Villemagne , Guillaume Cartron , Bernard Drenou , Beatrice Mahe , Omar Benbrahim , Xavier Cahu , Christelle Portois , Loic Ysebaert , Florence Nguyen Khac , Valerie Rouille , Alain Jacques Delmer BLOOD（2023）
AI 理解论文
溯源树
样例
